Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.
about
Latent autoimmune diabetes of the adult: current knowledge and uncertaintyLess is more: the detrimental consequences of immunosuppressive therapy in the treatment of type-1 diabetes.Antigen-based immunotherapies do not prevent progression of recent-onset autoimmune diabetes: a systematic review and meta-analysis.
P2860
Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.
@ast
Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.
@en
Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.
@nl
type
label
Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.
@ast
Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.
@en
Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.
@nl
prefLabel
Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.
@ast
Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.
@en
Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.
@nl
P2093
P2860
P356
P1433
P1476
Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.
@en
P2093
Conny Gysemans
Hannelie Korf
Sofie Robert
P2860
P356
10.4161/ISL.24785
P577
2013-03-01T00:00:00Z